{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:15:39Z","timestamp":1779340539934,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1985,9,1]],"date-time":"1985-09-01T00:00:00Z","timestamp":494380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1985,9]]},"DOI":"10.1007\/bf00544063","type":"journal-article","created":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T13:56:19Z","timestamp":1100872579000},"page":"531-535","source":"Crossref","is-referenced-by-count":13,"title":["Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism"],"prefix":"10.1007","volume":"28","author":[{"given":"A.","family":"Ulmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Le Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Husson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sassano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Menard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/0003-4819-85-5-630","volume":"85","author":"DL Loriaux","year":"1976","unstructured":"Loriaux DL, Menard R, Taylor A, Pita JC, Santen R (1976) Spironolactone and endocrine dysfunction. Ann Int Med 85: 630?636","journal-title":"Ann Int Med"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0022-4731(82)90412-5","volume":"17","author":"V Torelli","year":"1982","unstructured":"Torelli V, Hardy M, Nedelec L, Tournemine C, Deraedt R, Philibert D (1982) 7?-alkyl steroidal spironolactones as potent aldosterone antagonists. J Steroid Biochem 17, Abst no 198","journal-title":"J Steroid Biochem"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0022-4731(84)90395-9","volume":"20","author":"I Perroteau","year":"1984","unstructured":"Perroteau I, Netchitailo P, Delarue C, Leboulenger F, Philibert D, Deraedt R, Vaudry H (1984) J Steroid Biochem 20: 853?856","journal-title":"J Steroid Biochem"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cpt1976202167","volume":"20","author":"L Ramsay","year":"1976","unstructured":"Ramsay L, Shelton J, Harrison I, Tidd M, Asbury M (1976) Spironolactone and potassium canrenoate in normal man. Clin Pharmacol Ther 20: 167?177","journal-title":"Clin Pharmacol Ther"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00607423","volume":"12","author":"J Casals-Stenzel","year":"1977","unstructured":"Casals-Stenzel J, Schmalbach J, Losert W (1977) Improved method for comparative evaluation of aldosterone antagonists in healthy man. Eur J clin Pharmacol 12: 247?255","journal-title":"Eur J clin Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/endo-108-2-517","volume":"108","author":"WR Adam","year":"1981","unstructured":"Adam WR, Funder JW, Ulick S (1981) Orally active mineralocorticoid agonists and antagonists: ?-derivatives of aldosterone and 18-deoxyaldosterone. Endocrinology 108: 517?521","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"CR7","first-page":"219S","volume":"45","author":"F Mantero","year":"1973","unstructured":"Mantero F, Armanini D, Urbani S (1973) Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension. Clin Sci Mol Med 45 [Suppl 1]: 219S-224S","journal-title":"Clin Sci Mol Med"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0026-0495(79)90201-4","volume":"28","author":"MG Nicholls","year":"1979","unstructured":"Nicholls MG, Ramsay LE, Boddy K, Fraser R, Morton JJ, Robertson JIS (1979) Mineralocorticoid-induced blood pressure, electrolyte, and hormone changes, and reversal with spironolactone, in healthy men. Metabolism 28: 584?593","journal-title":"Metabolism"},{"key":"CR9","first-page":"49","volume":"4","author":"GT McInnes","year":"1982","unstructured":"McInnes GT, Shelton JR, Ramsay LE (1982) Evaluation of aldosterone antagonists in healthy man. Methods Find Exp Clin Pharmacol 4: 49?71","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2125.1975.tb01587.x","volume":"2","author":"LE Ramsay","year":"1975","unstructured":"Ramsay LE, Hessian P, Tidd MJ (1975) Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug response. Br J Clin Pharmacol 2: 271?276","journal-title":"Br J Clin Pharmacol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0026-0495(74)90095-X","volume":"23","author":"DJ Morris","year":"1974","unstructured":"Morris DJ, Davis RP (1974) Aldosterone: current concepts. Metabolism 23: 473?494","journal-title":"Metabolism"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM197506192922506","volume":"292","author":"RF Sjark","year":"1975","unstructured":"Sjark RF, Arky RA, Boulter PR, Sandek CD, O'Brian JT (1975) Renin, aldosterone and glucagon in the natriuresis of fasting. New Engl J Med 292: 1335?1340","journal-title":"New Engl J Med"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI108463","volume":"58","author":"RA Fronzo De","year":"1976","unstructured":"De Fronzo RA, Goldberg S, Agus ZS (1976) The effects of glucose and insulin on renal electrolyte transport. J Clin Invest 58: 83?90","journal-title":"J Clin Invest"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00544063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00544063\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00544063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T22:36:02Z","timestamp":1554417362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00544063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1985,9]]}},"alternative-id":["BF00544063"],"URL":"https:\/\/doi.org\/10.1007\/bf00544063","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,9]]}}}